Upgrade to enjoy subscriber-only features like email alerts and data export. See the Plans and Pricing

Serving hundreds of leading biopharmaceutical companies globally:

Teva
Express Scripts
Federal Trade Commission
Citi
Daiichi Sankyo
Mallinckrodt
Colorcon
Healthtrust
Dow

Generated: April 20, 2018

DrugPatentWatch Database Preview

Details for Patent: 4,839,364

« Back to Dashboard

Title: 9-Amino-3,4-dihydroacridines and related compounds useful for enhancing memory
Abstract:There are disclosed compounds having the formula ##STR1## wherein n is 1, 2 or 3; X is hydrogen, loweralkyl, loweralkoxy, halogen, hydroxy, nitro, trifluoromethyl, NHCOR.sub.2 where R.sub.2 is loweralkyl, or NR.sub.3 R.sub.4 where R.sub.3 and R.sub.4 are independently hydrogen or loweralkyl; R is hydrogen or loweralkyl; R.sub.1 is hydrogen, loweralkyl, diloweralkylaminoloweralkyl, arylloweralkyl, diarylloweralkyl, furylloweralkyl, thienylloweralkyl, oxygen-bridged arylloweralkyl, oxygen-bridged diarylloweralkyl, oxygen-bridged furylloweralkyl or oxygen-bridged thienylloweralkyl; Y is C.dbd.O or CR.sub.5 OH where R.sub.5 is hydrogen or loweralkyl; Z is CH.sub.2 or C.dbd.CR.sub.6 R.sub.7 where R.sub.6 and R.sub.7 are independently hydrogen or loweralkyl; or Y and Z taken together is CR.sub.5 .dbd.Ch where CR.sub.5 and CH correspond to Y and Z respectively; an optical antipode thereof, or a pharmaceutically acceptable acid addition salt thereof, which are useful for enhancing memory, methods for synthesizing them, and pharmaceutical compositions comprising an effective memory enhancing amount of such a compound.
Inventor(s): Shutske; Gregory M. (Somerset, NJ), Pierrat; Frank A. (Coventry, RI)
Assignee: Hoechst-Roussel Pharmaceuticals, Inc. (Somerville, NJ)
Filing Date:Jan 28, 1987
Application Number:07/007,885
Claims:1. A compound of the formula ##STR20## wherein n is 1, 2 or 3; X is hydrogen, loweralkyl, loweralkoxy, halogen, hydroxy, nitro, trifluomethyl, NHCOR.sub.2 where R.sub.2 is loweralkyl, or NR.sub.3 R.sub.4 where R.sub.3 and R.sub.4 are independently hydrogen or loweralkyl; R is hydrogen or loweralkyl; R.sub.1 is hydrogen, loweralkyl, diloweralkylaminoloweralkyl, arylloweralkyl, diarylloweralkyl, furylloweralkyl, thienylloweralkyl, oxygen-bridged arylloweralkyl, oxygen-bridged diarylloweralkyl, oxygen-bridged furylloweralkyl, oxygen-bridged thienylloweralkyl; Y is CR.sub.5, R.sub.5 being hydrogen or loweralkyl; and Z is CH; and optical antipode thereof, or a pharmaceutically acceptable acid addition salt thereof.

2. The compound as defined in claim 1, where n is 2.

3. The compound as defined in claim 2, where R is H.

4. The compound as defined in claim 3, where Y is CH and Z is CH.

5. The compound as defined in claim 1, where n is 1.

6. The compound as defined in claim 5, where R is H.

7. The compound as defined in claim 6, where Y and Z taken together is CH.dbd.CH.

8. The compound as defined in claim 1, which is 9-amino-3,4-dihydroacridine.

9. A pharmaceutical composition which comprises an effective memory enhancing amount of a compound defined in claim 1.

10. A pharmaceutical composition which comprises an effective memory enhancing amount of a compound defined in claim 2.

11. A pharmaceutical composition which comprises an effective memory enhancing amount of a compound defined in claim 5.

12. A method of treating a patient in need of memory enhancement, wherein an effective memory enhancing amount of a compound defined in claim 1 is administered to the patient.

13. A method of treating a patient in need of memory enhancement, wherein an effective memory enhancing amount of a compound defined in claim 2 is administered to the patient.

14. A method of treating a patient in need of memory enhancement, wherein an effective memory enhancing amount of a compound defined in claim 5 is administered to the patient.

For more information try a trial or see the plans and pricing

Serving hundreds of leading biopharmaceutical companies globally:

Mallinckrodt
US Army
Accenture
Colorcon
US Department of Justice
Queensland Health
Moodys
Daiichi Sankyo
Dow

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.